Synedgen Welcomes Dr. Hal J. Oien to Board of Directors
Synedgen, Inc. is thrilled to announce that Dr. Hal J. Oien has joined its board of directors. His appointment reflects the invaluable contributions he has made as a respected member of the Scientific Advisory Board, showcasing his vast scientific knowledge and visionary insights.
Words from the President and CEO
Shenda Baker, PhD, the President and CEO of Synedgen, shared her excitement about Dr. Oien’s new role. She remarked, “His clinical and commercial expertise will be invaluable as our Multivalent Innate Immune Signaling Target (MIIST) pipeline assets advance through the clinical phase.” This statement underscores the strategic importance of Dr. Oien’s background for the company's future ventures in biomedicine.
A Distinguished Career Journey
Dr. Oien's impressive career spans more than forty years, during which he has utilized his biomedical science background to create entrepreneurial endeavors. As the President of Jordco Inc., he oversees product development, sales, and operations, extending across various regions including Europe, Australia, and New Zealand.
In the past few years, he co-founded H2O Molecular, Inc., a groundbreaking biotechnology firm focused on microbial and oncological signatures associated with public water systems nationwide. His earlier achievements also include the strategic launch and successful sale of Interventional Hemostasis Products, Inc. to Advanced Vascular Dynamics, where he held the President position since the company began in 1992.
Expertise in Regulation and Leadership
Dr. Oien's robust regulatory background has been pivotal in developing FDA-cleared technologies that are patented and marketed globally. He is recognized as a key opinion leader among both civilian and government agencies, as well as in international collaborations.
In addition to his career accomplishments, Dr. Oien is honored as a philanthropist and an active community member in his home state. He earned a B.S. in Psychology from the University of California, Davis, a B.S. in General Science from the University of Oregon, and a D.M.D from the Oregon Health & Science University.
About Synedgen, Inc.
Synedgen, Inc. is at the forefront of biotechnology, dedicated to developing Multivalent Innate Immune Signaling Target (MIIST) therapeutics that aim to enhance and modulate the innate immune system. Their leading candidate, MIIST305, is currently in development as an innovative oral therapy intended for ulcerative colitis, showing promise in managing this complex condition.
Moreover, with the backing of the US Government, MIIST305 is also being investigated as a potential medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The technology is supported by extensive clinical validation and a rich body of peer-reviewed research, bolstered by twenty-two National Institutes of Health grants and Department of Defense contracts. Synedgen operates a state-of-the-art in-house GMP manufacturing facility, ensuring that they maintain high standards of product development and safety.
Frequently Asked Questions
What role will Dr. Hal J. Oien play at Synedgen?
Dr. Oien will utilize his clinical and commercial expertise to help advance the company’s pipeline assets, particularly the MIIST program.
What is Synedgen’s main area of focus?
Synedgen primarily concentrates on creating therapeutics that enhance the innate immune system, especially for gastrointestinal diseases.
What is the significance of MIIST305 in Synedgen's portfolio?
MIIST305 serves as the lead candidate for treating ulcerative colitis and is also being explored as a countermeasure for radiation syndrome.
What previous successes does Dr. Oien bring to Synedgen?
Dr. Oien has a varied background that includes successful entrepreneurial endeavors and advancements in biotechnology leading to FDA-approved products.
Where can I learn more about Synedgen, Inc.?
For more information on Synedgen, Inc. and its groundbreaking work, please visit their official website.
